☆ 4.6 Review

Antiviral Drug Discovery for the Treatment of COVID-19 Infections

VIRUSES-BASEL (2022)

Related references

Note: Only part of the references are listed.

Article Medicine, General & Internal

Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants

Emma K. Accorsi et al.

Summary: Assessing the performance of COVID-19 vaccines against the Omicron variant is crucial for public health guidance. This study found that receiving three doses of mRNA COVID-19 vaccine was associated with a lower likelihood of symptomatic SARS-CoV-2 infection compared to being unvaccinated or receiving two doses. These findings suggest that three doses of mRNA vaccine provide protection against both Omicron and Delta variants, though the protection against Omicron may be slightly lower.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)

Add to Collection

Article Chemistry, Medicinal

Design of SARS-CoV-2 PLpro Inhibitors for COVID-19 Antiviral Therapy Leveraging Binding Cooperativity

Zhengnan Shen et al.

Summary: Researchers have discovered a new antiviral drug that targets the SARS-CoV-2 papain-like protease (PLpro) to inhibit viral replication and improve antiviral potency in human cells.

JOURNAL OF MEDICINAL CHEMISTRY (2022)

Add to Collection

Article Chemistry, Medicinal

Design and Evaluation of a Novel Peptide-Drug Conjugate Covalently Targeting SARS-CoV-2 Papain-like Protease

Na Liu et al.

Summary: In this study, a novel peptide-drug conjugate was designed to inhibit PLpro in COVID-19. The drug showed promising antiviral effects in vitro and provides a potential option for antiviral drug design.

JOURNAL OF MEDICINAL CHEMISTRY (2022)

Add to Collection

Article Multidisciplinary Sciences

Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift

Elisabetta Cameroni et al.

Summary: The Omicron variant of SARS-CoV-2 has raised concerns due to its 37 amino acid substitutions in the spike protein, particularly in the receptor-binding domain (RBD), leading to increased binding affinity with human ACE2. Neutralizing activity against Omicron was greatly reduced in convalescent and vaccinated individuals compared to the ancestral virus, but this decrease was less significant after a third vaccine dose. Broadly neutralizing monoclonal antibodies recognizing conserved RBD epitopes may be crucial in combating the Omicron variant and future zoonotic transmissions.

NATURE (2022)

Add to Collection

Article Multidisciplinary Sciences

Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies

Yunlong Cao et al.

Summary: The Omicron variant of SARS-CoV-2 contains 15 mutations in the receptor-binding domain, leading to evasion of over 85% of tested neutralizing antibodies. Different epitope groups of neutralizing antibodies are affected to varying degrees by single mutations of Omicron. Antibodies targeting the conserved region of sarbecovirus remain most effective against Omicron.

NATURE (2022)

Add to Collection

Article Medicine, General & Internal

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients

A. Jayk Bernal et al.

Summary: This study found that early treatment with molnupiravir reduced the risk of hospitalization or death in at-risk, unvaccinated adults with Covid-19.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Multidisciplinary Sciences

Structural basis for continued antibody evasion by the SARS-CoV-2 receptor binding domain

Katherine G. Nabel et al.

Summary: This study evaluates the impact of SARS-CoV-2 variants on neutralizing antibody activity and reveals that simultaneous antibody escape mutations make the virus more resistant to neutralization. Additionally, the study finds that the virus can acquire glycan to escape neutralization.

SCIENCE (2022)

Add to Collection

Article Cell Biology

A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection

Panpan Zhou et al.

Summary: This study describes a broadly neutralizing antibody CC40.8 that targets the spike fusion machinery of coronaviruses and demonstrates its protective efficacy against SARS-CoV-2 in animal models, indicating its potential for the development of pan-coronavirus vaccines.

SCIENCE TRANSLATIONAL MEDICINE (2022)

Add to Collection

Article Cell Biology

Structural basis and mode of action for two broadly neutralizing antibodies against SARS-CoV-2 emerging variants of concern

Wenwe Li et al.

Summary: This study elucidates the structural basis and mode of action for two potent SARS-CoV-2 spike-neutralizing monoclonal antibodies. CV3-1 triggers shedding of the S1 subunit by binding to a loop structure in the receptor-binding domain (RBD), while CV3-25 inhibits membrane fusion by binding to an epitope in the stem helix region of the S2 subunit. Designing vaccine immunogens that incorporate conserved regions in the RBD and stem helix region could elicit pan-coronavirus protective immune responses.

CELL REPORTS (2022)

Add to Collection

Article Immunology

Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost

Jingwen Ai et al.

Summary: This study explored the immunogenicity of different vaccination strategies against the Omicron variant of SARS-CoV-2. The results showed that the Omicron variant has a high immune escape ability compared to other variants, but heterologous protein subunit vaccines and homologous inactivated vaccine boosters can improve neutralization against Omicron.

EMERGING MICROBES & INFECTIONS (2022)

Add to Collection

Article Chemistry, Medicinal

Structure-Based Optimization of ML300-Derived, Noncovalent Inhibitors Targeting the Severe Acute Respiratory Syndrome Coronavirus 3CL Protease (SARS-CoV-2 3CLPro)

Sang Hoon Han et al.

Summary: Starting from ML300, a structure-based optimization campaign was conducted against the SARS-CoV-2 main protease, resulting in the discovery of compound 41 with antiviral activity. This study provides important insights for the development of antiviral drugs in combating SARS-like coronavirus outbreaks.

JOURNAL OF MEDICINAL CHEMISTRY (2022)

Add to Collection

Article Cell Biology

LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants

Kathryn Westendorf et al.

Summary: A monoclonal antibody named LY-CoV1404 has been successfully isolated, which demonstrates highly potent neutralization against multiple variants of the SARS-CoV-2 virus. The binding site of LY-CoV1404 remains relatively conserved, allowing it to maintain its activity. This finding suggests that LY-CoV1404 has the potential to be an effective therapeutic agent against all known variants.

CELL REPORTS (2022)

Add to Collection

Article Chemistry, Medicinal

Validation and Invalidation of SARS-CoV-2 Papain-like Protease Inhibitors

Chunlong Ma et al.

Summary: The study aimed to validate a range of compounds as SARS-CoV-2 PLpro inhibitors, but results showed that these compounds did not exhibit effective inhibition of PLpro at both enzymatic and cellular levels. Therefore, further efforts are needed to search for more potent and specific SARS-CoV-2 PLpro inhibitors.

ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE (2022)

Add to Collection

Article Pharmacology & Pharmacy

Crystal structure of SARS-CoV-2 papain-like protease

Xiaopan Gao et al.

Summary: This study provided structural frameworks for PLpro inhibitor design targeting SARS-CoV-2, showing that existing SARS-CoV PLpro inhibitors have some efficacy against SARS-CoV-2 and explored the inhibition mechanism of GRL0617.

ACTA PHARMACEUTICA SINICA B (2021)

Add to Collection

Review Pharmacology & Pharmacy

Can drug repurposing strategies be the solution to the COVID-19 crisis?

Carolina L. Bellera et al.

Summary: The COVID-19 pandemic has resulted in significant human and economic costs, making drug repurposing an attractive option for finding short-term treatments. Most current clinical trials are examples of drug repurposing, with caution needed to manage expectations and avoid overconfidence in conclusions drawn from scientific reports.

EXPERT OPINION ON DRUG DISCOVERY (2021)

Add to Collection

Article Medicine, General & Internal

Repurposed Antiviral Drugs for Covid-19-Interim WHO Solidarity Trial Results

Summary: The authors of the study reported the interim results of using four repurposed antiviral drugs (remdesivir, hydroxychloroquine, lopinavir, and interferon beta-1a) in hospitalized COVID-19 patients. The study showed that these drug regimens had little or no effect on overall mortality, initiation of ventilation, and duration of hospital stay.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody

C. Garrett Rappazzo et al.

Summary: The engineered antibody ADG-2 shows enhanced neutralization breadth and potency against a wide range of sarbecoviruses, providing complete protection in SARS and COVID-19 mouse models. Structural and biochemical studies reveal that ADG-2 targets a highly conserved epitope through a unique angle of approach.

SCIENCE (2021)

Add to Collection

Review Virology

Structural Analysis of Neutralizing Epitopes of the SARS-CoV-2 Spike to Guide Therapy and Vaccine Design Strategies

Maxwell T. Finkelstein et al.

Summary: This review summarizes recent studies focusing on the development of monoclonal antibodies and vaccines against SARS-CoV-2. By studying the structural details of the virus, important information for the treatment and prevention of COVID-19 can be obtained.

VIRUSES-BASEL (2021)

Add to Collection

Article Microbiology

Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets

Robert M. Cox et al.

Summary: Treating SARS-CoV-2-infected ferrets with nucleoside analogue MK-4482/EIDD-2801 reduced viral load and suppressed virus spread. This therapeutic approach shows promise in breaking transmission chains of the COVID-19 pandemic.

NATURE MICROBIOLOGY (2021)

Add to Collection

Article Multidisciplinary Sciences

A multi-pronged approach targeting SARS-CoV-2 proteins using ultra-large virtual screening

Christoph Gorgulla et al.

Summary: The global effort to combat the ongoing COVID-19 pandemic has led to promising prophylactic measures, but there is still a need for effective therapeutics. Through a large-scale virtual screening platform, inhibitors targeting SARS-CoV-2 are being searched for, focusing on both viral enzymes' active sites and critical protein-protein interactions.

ISCIENCE (2021)

Add to Collection

Article Microbiology

Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity against SARS-CoV-2

Wendy P. Painter et al.

Summary: Molnupiravir showed rapid appearance and dose-proportional increase in plasma, with good tolerability in healthy volunteers. The study evaluated single and multiple doses of molnupiravir and the impact of food on pharmacokinetics in subjects, showing no accumulation following multiple doses and a decrease in absorption rate when administered with food, but no decrease in overall exposure.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)

Add to Collection

Article Microbiology

AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2 In Vitro and a Promising Oral Antiviral for Treatment of COVID-19

Steven S. Good et al.

Summary: AT-527, an oral antiviral drug, has potent activity against various coronaviruses, including SARS-CoV-2. In vitro experiments have shown that AT-511 has high efficacy in inhibiting the replication of SARS-CoV-2, with minimal cytotoxicity. Studies suggest that AT-527 may be an effective treatment option for COVID-19.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity

Emma C. Thomson et al.

Summary: SARS-CoV-2 virus can mutate and evade immunity, with mutations like N439K conferring resistance against neutralizing monoclonal antibodies and enhancing binding affinity to hACE2 receptor. Despite similar in vitro replication fitness and clinical outcomes compared to wild type, N439K mutation highlights the importance of ongoing molecular surveillance for guiding vaccine and therapeutic development and usage.

CELL (2021)

Add to Collection

Review Medicine, Research & Experimental

Remdesivir for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials

Ahmad Al-Abdouh et al.

Summary: Remdesivir in COVID-19 patients is associated with increased rates of recovery and hospital discharge, along with decreased rates of serious adverse events. However, it does not significantly reduce the time to clinical improvement or mortality.

CONTEMPORARY CLINICAL TRIALS (2021)

Add to Collection

Article Medicine, General & Internal

Waning Immunity after the BNT162b2 Vaccine in Israel

Yair Goldberg et al.

Summary: The immunity against the delta variant of SARS-CoV-2 waned in all age groups in Israel a few months after receiving the second dose of the vaccine, leading to an increase in infection and severe cases.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Review Pharmacology & Pharmacy

Drug repurposing for COVID-19: Approaches, challenges and promising candidates

Yan Ling Ng et al.

Summary: Drug repurposing is gaining attention as an alternative to traditional drug development due to its lower risk and time-saving advantages. Computational and experimental approaches are commonly used in drug repurposing strategies.

PHARMACOLOGY & THERAPEUTICS (2021)

Add to Collection

Article Multidisciplinary Sciences

An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19

Dafydd R. Owen et al.

Summary: PF-07321332, an orally bioavailable SARS-CoV-2 main protease inhibitor, has been discovered with in vitro pan-human coronavirus antiviral activity and excellent off-target selectivity and in vivo safety profiles. This new drug has shown promise in countering the threat of COVID-19 with its oral activity and safety in clinical trials.

SCIENCE (2021)

Add to Collection

Article Multidisciplinary Sciences

Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors

Jerzy Osipiuk et al.

Summary: The study focused on papain-like protease (PLpro) as a potential target for antivirals against SARS-CoV-2, identifying inhibitors and their interactions with the enzyme. The findings demonstrate the potential for developing high-affinity inhibitors through structure-based drug design efforts targeting PLpro.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Multidisciplinary Sciences

Identification of ebselen and its analogues as potent covalent inhibitors of papain-like protease from SARS-CoV-2

Ewelina Weglarz-Tomczak et al.

Summary: Organoselenium compounds were identified as a novel approach for inhibiting the activity of PL(pro)CoV2, with inhibitors showing potency in the nanomolar range for the first time. Differences between PLpro from SARS and CoV2 were also found, potentially correlating with the diverse dynamics of their replication and disease progression.

SCIENTIFIC REPORTS (2021)

Add to Collection

Article Virology

Viral polymerase binding and broad-spectrum antiviral activity of molnupiravir against human seasonal coronaviruses

Yining Wang et al.

Summary: The study demonstrates that molnupiravir effectively inhibits the replication and production of infectious viruses of seasonal coronaviruses by targeting RNA-dependent RNA polymerase in cell culture models. Furthermore, when combined with the protease inhibitor GC376, it shows enhanced antiviral activity, highlighting its potential for treating patients infected with seasonal coronaviruses.

VIROLOGY (2021)

Add to Collection

Article Multidisciplinary Sciences

Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19

Britton Boras et al.

Summary: Researchers found that PF-07304814 exhibits broad-spectrum activity in inhibiting SARS-CoV and SARS-CoV-2, supported by its ADME and safety profile for clinical development. The 3CL protease, crucial in various coronaviruses, is effectively inhibited by PF-00835231 as a single agent, and shows even better results in combination with remdesivir.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Chemistry, Multidisciplinary

Potent Noncovalent Inhibitors of the Main Protease of SARS-CoV-2 from Molecular Sculpting of the Drug Perampanel Guided by Free Energy Perturbation Calculations

Chun-Hui Zhang et al.

Summary: Starting from known drugs, the study redesigned perampanel into potent noncovalent inhibitors of SARS-CoV-2 main protease with ca. 20 nM IC50 values. Free-energy perturbation calculations and high-resolution X-ray crystal structures guided the design efforts and rapid development of effective analogues. Cell-based antiviral assays confirmed the potential of the compounds for COVID-19 treatment, highlighting the power of computational chemistry in drug discovery.

ACS CENTRAL SCIENCE (2021)

Add to Collection

Article Cell Biology

Stabilized coronavirus spike stem elicits a broadly protective antibody

Ching-Lin Hsieh et al.

Summary: This study developed stabilized stem (SS) antigens by removing the S1 subunit from the Middle East respiratory syndrome (MERS)-CoV spike (S) glycoprotein using structure-guided protein engineering. Vaccination with MERS SS elicited cross-reactive b-CoV antibody responses and protected mice against lethal MERS-CoV challenge. The discovery of a panel of cross-reactive monoclonal antibodies, among which IgG22 showed high affinity binding to both MERS-CoV and severe acute respiratory syndrome (SARS)-CoV-2 S proteins, indicates the potential for cross-reactive CoV antibodies.

CELL REPORTS (2021)

Add to Collection

Article Virology

Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19

George R. Painter et al.

Summary: Although vaccines are available, there is still a critical need for antiviral drugs with potent activity against SARS-CoV-2, especially for immunosuppressed individuals and emerging variants. Molnupiravir evolved from preclinical development for influenza to a potential COVID-19 treatment, with the development timeline accelerated significantly to focus on coronavirus infections. Collaboration with regulatory authorities in real time played a key role in expediting the program.

CURRENT OPINION IN VIROLOGY (2021)

Add to Collection

Article Biochemistry & Molecular Biology

ALG-097111, a potent and selective SARS-CoV-2 3-chymotrypsin-like cysteine protease inhibitor exhibits in vivo efficacy in a Syrian Hamster model

Koen Vandyck et al.

Summary: There is an urgent need for antivirals targeting SARS-CoV-2 virus. SARS-CoV-2 main protease (3CLpro) is a promising target for antiviral therapy, but selectivity issues of inhibitors need to be addressed. ALG-097111 demonstrated potent inhibition of SARS-CoV-2 3CLpro in vivo, providing evidence for its potential as a therapeutic target.

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2021)

Add to Collection

Article Chemistry, Multidisciplinary

Michaelis-like complex of SARS-CoV-2 main protease visualized by room-temperature X-ray crystallography

Daniel W. Kneller et al.

Summary: SARS-CoV-2 main protease (M-pro) is essential for viral replication and serves as a crucial drug target. The study provides insights into the catalytic mechanism of M-pro and demonstrates that the catalytic site is pre-organized for catalysis before substrate binding. This structure is ideal for in silico modeling of the SARS-CoV-2 M-pro catalytic mechanism.

IUCRJ (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template

Calvin J. Gordon et al.

Summary: The study found that Molnupiravir or NHC can increase the mutation frequencies in replicating coronaviruses, leading to enhanced antiviral effects; NHC-TP primarily competes with CTP for incorporation, resulting in RNA mutations; Biochemical data support a mechanism of action of Molnupiravir that is primarily based on RNA mutagenesis mediated via the template strand.

JOURNAL OF BIOLOGICAL CHEMISTRY (2021)

Add to Collection

Article Immunology

β-D-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells

Shuntai Zhou et al.

Summary: Mutagenic ribonucleosides can serve as broad-spectrum antiviral agents, but may pose risks to the host due to their host mutagenic activity in addition to antiviral activity.

JOURNAL OF INFECTIOUS DISEASES (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Structural basis for broad coronavirus neutralization

Maximilian M. Sauer et al.

Summary: The study identified a monoclonal antibody, B6, that can cross-react with eight beta-coronavirus spike proteins from three viral lineages, targeting a conserved cryptic epitope for potential broad coronavirus neutralization, marking a potential breakthrough in pan-beta-coronavirus vaccine design.

NATURE STRUCTURAL & MOLECULAR BIOLOGY (2021)

Add to Collection

Review Virology

Broad-Spectrum Antiviral Strategies and Nucleoside Analogues

Robert J. Geraghty et al.

Summary: The emergence or re-emergence of viruses with epidemic and pandemic potential poses significant human health threats, and although vaccines are key in controlling virus spread, their development may face obstacles such as safety concerns. Developing broad-spectrum antiviral molecules, particularly nucleoside analogues, for a fast response in emergency situations is crucial in combating outbreak crises.

VIRUSES-BASEL (2021)

Add to Collection

Article Multidisciplinary Sciences

Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model

Kyle Rosenke et al.

Summary: Orally administered nucleoside analog MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model, with an inhibitory effect observed whether the drug is given 12 hours before or 12 hours after infection. This suggests the potential of MK-4482 for controlling SARS-CoV-2 infection in humans following high-risk exposure and for treating COVID-19 patients.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Multidisciplinary Sciences

A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies

Chunyan Wang et al.

Summary: Research has isolated two human monoclonal antibodies from immunized humanized mice that display cross-reactivity against various beta coronaviruses, targeting the stem helix in the spike S2 fusion subunit. These antibodies block MERS-CoV infection in cells and provide protection against lethal MERS-CoV challenge in mice, showcasing their potential for developing broad-spectrum antibodies. Despite exhibiting cross-reactivity, the antibodies only neutralize MERS-CoV due to subtle epitope differences in the spike S2 fusion subunit.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Microbiology

The furin cleavage site in the SARS-CoV-2 spike protein is required for transmission in ferrets

Thomas P. Peacock et al.

Summary: Efficient transmission of SARS-CoV-2 among infected ferrets is dependent on a functional furin cleavage site in the spike protein. The virus has a selective advantage in lung cells and primary human airway epithelial cells due to a polybasic insertion, but replication may be impaired in certain cell lines.

NATURE MICROBIOLOGY (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Current Strategies of Antiviral Drug Discovery for COVID-19

Miao Mei et al.

Summary: SARS-CoV-2 is a novel coronavirus that has caused the global COVID-19 pandemic, with no effective antiviral drugs currently available, leading to the urgent need for research and development of new treatment strategies.

FRONTIERS IN MOLECULAR BIOSCIENCES (2021)

Add to Collection

Article Chemistry, Medicinal

Key Interacting Residues between RBD of SARS-CoV-2 and ACE2 Receptor: Combination of Molecular Dynamics Simulation and Density Functional Calculation

Bahaa Jawad et al.

Summary: This study systematically analyzed the binding mechanism between the spike protein of SARS-CoV-2 and the ACE2 receptor, identifying key interacting amino acids. The research confirmed key residues responsible for tight binding with ACE2 and slightly different interacting amino acids in the Alpha and Beta variants.

JOURNAL OF CHEMICAL INFORMATION AND MODELING (2021)

Add to Collection

Article Immunology

Molnupiravir Inhibits Replication of the Emerging SARS-CoV-2 Variants of Concern in a Hamster Infection Model

Rana Abdelnabi et al.

Summary: The emergence of SARS-CoV-2 variants of concern has worsened the COVID-19 pandemic, with current monoclonal antibodies and vaccines showing reduced efficacy against some of these variants. However, antivirals targeting conserved proteins of SARS-CoV-2 are likely to remain effective. Research on molnupiravir has shown effectiveness against different variants, highlighting its potential in combating current and future variants.

JOURNAL OF INFECTIOUS DISEASES (2021)

Add to Collection

Editorial Material Multidisciplinary Sciences

A white-knuckle ride of open COVID drug discovery

Frank von Delft et al.

NATURE (2021)

Add to Collection

Article Multidisciplinary Sciences

Systems vaccinology of the BNT162b2 mRNA vaccine in humans

Prabhu S. Arunachalam et al.

Summary: The study found that vaccination with the Pfizer-BioNTech mRNA vaccine can induce immune responses against neutralizing antibodies and CD4, CD8 T cells of SARS-CoV-2. Booster vaccines can significantly enhance innate immune responses, and different innate pathways associated with CD8 T cells and neutralizing antibodies have been identified.

NATURE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis

Florian Kabinger et al.

Summary: Molnupiravir is an oral antiviral drug candidate that increases viral RNA mutations frequency and inhibits replication of SARS-CoV-2 by altering the substrate preference of RdRp. This two-step mutagenesis mechanism can explain the broad-spectrum antiviral activity of molnupiravir, making it a promising COVID-19 treatment option.

NATURE STRUCTURAL & MOLECULAR BIOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months

S. J. Thomas et al.

Summary: BNT162b2 vaccine remains highly effective and safe over the course of 6 months post-vaccination, with efficacy rates ranging from 86% to 100% across different demographics and risk factors for Covid-19. The vaccine also shows a high efficacy against severe disease, with particularly promising results observed in South Africa against the B.1.351 variant.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

Drugs repurposed for COVID-19 by virtual screening of 6,218 drugs and cell-based assay

Woo Dae Jang et al.

Summary: The study team successfully identified 15 and 23 potential repurposed drugs for COVID-19 from 6,218 approved and clinical trial drugs, with seven of them showing the ability to inhibit SARS-CoV-2 replication in Vero cells. Additionally, three drug combinations exhibited strong synergistic effects in inhibiting SARS-CoV-2, improving antiviral efficacy and reducing the risk of drug toxicity.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)

Add to Collection

Article Multidisciplinary Sciences

Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants

Amarendra Pegu et al.

Summary: The study assessed the impact of SARS-CoV-2 variants on antibody responses induced by the mRNA vaccine over 7 months, showing that most individuals maintained binding and functional antibodies against variants, with B.1.351 having the lowest antibody recognition.

SCIENCE (2021)

Add to Collection

Article Virology

Structure and function of SARS-CoV-2 polymerase

Hauke S. Hillen

Summary: Coronaviruses use RNA-dependent RNA polymerase (RdRp) to replicate their genome. Recent structural data on SARS-CoV-1 RdRp and SARS-CoV-2 polymerase have provided insight into coronavirus genome expression and replication mechanisms.

CURRENT OPINION IN VIROLOGY (2021)

Add to Collection

Article Chemistry, Multidisciplinary

Discovery of SARS-CoV-2 Papain-like Protease Inhibitors through a Combination of High-Throughput Screening and a FlipGFP-Based Reporter Assay

Chunlong Ma et al.

Summary: The study identified several PLpro inhibitors with improved enzymatic inhibition and antiviral activity, including Jun9-72-2 and Jun9-75-4, through high-throughput screening and lead optimization. The development of a cell-based FlipGFP assay allows for predicting cellular antiviral activity of PLpro inhibitors in the BSL-2 setting. X-ray crystal structure analysis and molecular dynamics simulations provided insights into the interactions of these inhibitors with PLpro.

ACS CENTRAL SCIENCE (2021)

Add to Collection

Article Chemistry, Physical

Incorporation efficiency and inhibition mechanism of 2′-substituted nucleotide analogs against SARS-CoV-2 RNA-dependent RNA polymerase

Congmin Yuan et al.

Summary: The ongoing pandemic caused by SARS-CoV-2 highlights the need for effective therapeutics. Inhibition of SARS-CoV-2 RdRp by nucleotide analogs offers a promising antiviral strategy. Research on 2'-modified nucleotides shows varying inhibitory effects on SARS-CoV-2 RdRp, which could potentially aid in the rational design of antiviral agents.

PHYSICAL CHEMISTRY CHEMICAL PHYSICS (2021)

Add to Collection

Review Chemistry, Medicinal

DNA-Encoded Chemical Libraries: A Comprehensive Review with Succesful Stories and Future Challenges

Adrian Gironda-Martinez et al.

Summary: DNA-encoded chemical libraries (DELs) are a versatile and powerful technology platform for discovering small-molecule ligands to protein targets. Advances in DNA-compatible reactions, selection methodologies, sequencing, and data analysis have enabled the construction and screening of libraries of unprecedented size, leading to the discovery of highly potent ligands. The Review provides an overview of diverse approaches for DEL generation and screening, highlighting recent success stories and future challenges in improving DEL technology for therapeutic discovery.

ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE (2021)

Add to Collection

Article Immunology

Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape

John S. Tregoning et al.

Summary: The development and rollout of vaccines have brought hope for controlling the COVID-19 pandemic, with vaccines proving highly effective in preventing disease. However, challenges remain in ensuring equitable access to vaccines globally, as well as lessons to be learned for controlling pandemics in the future.

NATURE REVIEWS IMMUNOLOGY (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Development of potent and selective inhibitors targeting the papain-like protease of SARS-CoV-2

Hengyue Shan et al.

Summary: This study describes the development of a potent and selective inhibitor for SCoV2 PLpro, which effectively blocks viral replication and provides a new method for evaluating SCoV2 PLpro inhibitors. The findings offer promising leads and important tools for drug discovery targeting SCoV2 PLpro.

CELL CHEMICAL BIOLOGY (2021)

Add to Collection

Article Biochemistry & Molecular Biology

The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus

Calvin J. Gordon et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2020)

Add to Collection

Article Medicine, General & Internal

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

Roujian Lu et al.

LANCET (2020)

Add to Collection

Article Multidisciplinary Sciences

A new coronavirus associated with human respiratory disease in China

Fan Wu et al.

NATURE (2020)

Add to Collection

Article Medicine, General & Internal

A Novel Coronavirus from Patients with Pneumonia in China, 2019

Na Zhu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Multidisciplinary Sciences

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2

Renhong Yan et al.

SCIENCE (2020)

Add to Collection

Article Multidisciplinary Sciences

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Daniel Wrapp et al.

SCIENCE (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2

Qihui Wang et al.

CELL (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Alexandra C. Walls et al.

CELL (2020)

Add to Collection

Article Immunology

Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies

Chunyan Yi et al.

CELLULAR & MOLECULAR IMMUNOLOGY (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency

Calvin J. Gordon et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2020)

Add to Collection

Article Immunology

Forty years with coronaviruses

Susan R. Weiss

JOURNAL OF EXPERIMENTAL MEDICINE (2020)

Add to Collection

Article Multidisciplinary Sciences

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors

Linlin Zhang et al.

SCIENCE (2020)

Add to Collection

Article Cell Biology

An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice

Timothy P. Sheahan et al.

SCIENCE TRANSLATIONAL MEDICINE (2020)

Add to Collection

Article Medicine, General & Internal

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

Yeming Wang et al.

LANCET (2020)

Add to Collection

Article Multidisciplinary Sciences

An open-source drug discovery platform enables ultra-large virtual screens

Christoph Gorgulla et al.

NATURE (2020)

Add to Collection

Article Multidisciplinary Sciences

Structure of replicating SARS-CoV-2 polymerase

Hauke S. Hillen et al.

NATURE (2020)

Add to Collection

Article Multidisciplinary Sciences

Cross-neutralization ofSARS-CoV-2 by a human monoclonal SARS-CoV antibody

Dora Pinto et al.

NATURE (2020)

Add to Collection

Article Multidisciplinary Sciences

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Jun Lan et al.

NATURE (2020)

Add to Collection

Article Multidisciplinary Sciences

Structural basis of receptor recognition by SARS-CoV-2

Jian Shang et al.

NATURE (2020)

Add to Collection

Article Multidisciplinary Sciences

Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors

Zhenming Jin et al.

NATURE (2020)

Add to Collection

Article Medicine, General & Internal

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19

Jason D. Goldman et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Medicine, General & Internal

Remdesivir for the Treatment of Covid-19-Final Report

John H. Beigel et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding

Tyler N. Starr et al.

CELL (2020)

Add to Collection

Article Chemistry, Medicinal

COVID-19: Drug Targets and Potential Treatments

Carmen Gil et al.

JOURNAL OF MEDICINAL CHEMISTRY (2020)

Add to Collection

Article Virology

Evolutionary arms race between virus and host drives genetic diversity in bat SARS related coronavirus spike genes

Hua Guo et al.

JOURNAL OF VIROLOGY (2020)

Add to Collection

Review Biochemistry & Molecular Biology

Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach

Ahmad Abu Turab Naqvi et al.

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2020)

Add to Collection

Article Cell Biology

Drugs targeting various stages of the SARS-CoV-2 life cycle: Exploring promising drugs for the treatment of Covid-19

Ramarao Poduri et al.

CELLULAR SIGNALLING (2020)

Add to Collection

Article Multidisciplinary Sciences

Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing

Laura Riva et al.

NATURE (2020)

Add to Collection

Article Multidisciplinary Sciences

Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity

Donghyuk Shin et al.

NATURE (2020)

Add to Collection

Article Multidisciplinary Sciences

A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2

Xiangyang Chi et al.

SCIENCE (2020)

Add to Collection

Article Multidisciplinary Sciences

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies

Alina Baum et al.

SCIENCE (2020)

Add to Collection

Article Multidisciplinary Sciences

Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail

Johanna Hansen et al.

SCIENCE (2020)

Add to Collection

Article Multidisciplinary Sciences

Distinct conformational states of SARS-CoV-2 spike protein

Yongfei Cai et al.

SCIENCE (2020)

Add to Collection

Article Medicine, General & Internal

Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19 A Randomized Clinical Trial

Christoph D. Spinner et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Template-dependent inhibition of coronavirus RNA-dependent RNA polymerase by remdesivir reveals a second mechanism of action

Egor P. Tchesnokov et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2020)

Add to Collection

Article Chemistry, Medicinal

Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19

Robert L. Hoffman et al.

JOURNAL OF MEDICINAL CHEMISTRY (2020)

Add to Collection

Article Multidisciplinary Sciences

Structures and distributions of SARS-CoV-2 spike proteins on intact virions

Zunlong Ke et al.

NATURE (2020)

Add to Collection

Review Virology

Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis

Dhan Bahadur Shrestha et al.

VIROLOGY JOURNAL (2020)

Add to Collection

Article Multidisciplinary Sciences

Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis

Ashleigh Shannon et al.

NATURE COMMUNICATIONS (2020)

Add to Collection

Article Multidisciplinary Sciences

Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication

Wayne Vuong et al.

NATURE COMMUNICATIONS (2020)

Add to Collection

Article Multidisciplinary Sciences

Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir

Steffen Jockusch et al.

SCIENTIFIC REPORTS (2020)

Add to Collection

Article Chemistry, Multidisciplinary

Beyond Shielding: The Roles of Glycans in the SARS-CoV-2 Spike Protein

Lorenzo Casalino et al.

ACS CENTRAL SCIENCE (2020)

Add to Collection

Article Multidisciplinary Sciences

Activity profiling and crystal structures of inhibitor-bound SARS-CoV-2 papain-like protease: A framework for anti-COVID-19 drug design

Wioletta Rut et al.

SCIENCE ADVANCES (2020)

Add to Collection

Article Chemistry, Medicinal

Ebselen, Disulfiram, Carmofur, PX-12, Tideglusib, and Shikonin Are Nonspecific Promiscuous SARS-CoV-2 Main Protease Inhibitors

Chunlong Ma et al.

ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE (2020)

Add to Collection

Article Pharmacology & Pharmacy

Nsp3 of coronaviruses: Structures and functions of a large multi-domain protein

Jian Lei et al.

ANTIVIRAL RESEARCH (2018)

Add to Collection

Editorial Material Multidisciplinary Sciences

Future of nonnucleoside reverse transcriptase inhibitors

Nicolas Sluis-Cremer

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)

Add to Collection

Article Virology

Mechanisms and Concepts in RNA Virus Population Dynamics and Evolution

Patrick T. Dolan et al.

ANNUAL REVIEW OF VIROLOGY, VOL 5 (2018)

Add to Collection

Article Biochemistry & Molecular Biology

The SARS-CoV Fusion Peptide Forms an Extended Bipartite Fusion Platform that Perturbs Membrane Order in a Calcium-Dependent Manner

Alex L. Lai et al.

JOURNAL OF MOLECULAR BIOLOGY (2017)

Add to Collection

Article Biochemistry & Molecular Biology

Recognition of Lys48-Linked Di-ubiquitin and Deubiquitinating Activities of the SARS Coronavirus Papain-like Protease

Miklos Bekes et al.

MOLECULAR CELL (2016)

Add to Collection

Review Pharmacology & Pharmacy

The SARS-coronavirus papain-like protease: Structure, function and inhibition by designed antiviral compounds

Yahira M. Baez-Santos et al.

ANTIVIRAL RESEARCH (2015)

Add to Collection

Article Virology

Host cell proteases: Critical determinants of coronavirus tropism and pathogenesis

Jean Kaoru Millet et al.

VIRUS RESEARCH (2015)

Add to Collection

Article Microbiology

In Vitro Activity and Resistance Profile of Dasabuvir, a Nonnucleoside Hepatitis C Virus Polymerase Inhibitor

Warren Kati et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)

Add to Collection

Article Multidisciplinary Sciences

Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430

Travis K. Warren et al.

NATURE (2014)

Add to Collection

Article Multidisciplinary Sciences

One severe acute respiratory syndrome coronavirus protein complex integrates processive RNA polymerase and exonuclease activities

Lorenzo Subissi et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)

Add to Collection

Article Virology

MERS-CoV papain-like protease has deISGylating and deubiquitinating activities

Anna M. Mielech et al.

VIROLOGY (2014)

Add to Collection

Article Biology

CORONAVIRUS GENOMICS AND BIOINFORMATICS ANALYSIS

Patrick C. Y. Woo et al.

OMICS IN CLINICAL PRACTICE: GENOMICS, PHARMACOGENOMICS, PROTEOMICS, AND TRANSCRIPTOMICS IN CLINICAL RESEARCH (2014)

Add to Collection

Article Cell Biology

Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4

Nianshuang Wang et al.

CELL RESEARCH (2013)

Add to Collection

Article Chemistry, Medicinal

Discovery, Synthesis, And Structure-Based Optimization of a Series of N-(tert-Butyl)-2-(N-arylamido)-2-(pyridin-3-yl) Acetamides (ML188) as Potent Noncovalent Small Molecule Inhibitors of the Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) 3CL Protease

Jon Jacobs et al.

JOURNAL OF MEDICINAL CHEMISTRY (2013)

Add to Collection

Article Medicine, General & Internal

Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia

Ali Moh Zaki et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

Add to Collection

Article Biochemistry & Molecular Biology

Polyubiquitin binding and cross-reactivity in the USP domain deubiquitinase USP21

Yu Ye et al.

EMBO REPORTS (2011)

Add to Collection

Article Chemistry, Medicinal

Severe Acute Respiratory Syndrome Coronavirus Papain-like Novel Protease Inhibitors: Design, Synthesis, Protein-Ligand X-ray Structure and Biological Evaluation

Arun K. Ghosh et al.

JOURNAL OF MEDICINAL CHEMISTRY (2010)

Add to Collection

Review Virology

Coronavirus Genomics and Bioinformatics Analysis

Patrick C. Y. Woo et al.

VIRUSES-BASEL (2010)

Add to Collection

Article Chemistry, Medicinal

Structure-Based Design, Synthesis, and Biological Evaluation of a Series of Novel and Reversible Inhibitors for the Severe Acute Respiratory Syndrome-Coronavirus Papain-Like Protease

Arun K. Ghosh et al.

JOURNAL OF MEDICINAL CHEMISTRY (2009)

Add to Collection

Article Biochemistry & Molecular Biology

Regulation of IRF-3-dependent innate immunity by the papain-like protease domain of the severe acute respiratory syndrome coronavirus

Santhana G. Devaraj et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2007)

Add to Collection

Article Virology

The papain-like protease from the severe acute respiratory syndrome coronavirus is a deubiquitinating enzyme

HA Lindner et al.

JOURNAL OF VIROLOGY (2005)

Add to Collection

Article Multidisciplinary Sciences

Structure of SARS coronavirus spike receptor-binding domain complexed with receptor

F Li et al.

SCIENCE (2005)

Add to Collection

Article Virology

Identification of severe acute respiratory syndrome coronavirus replicase products and characterization of papain-like protease activity

BH Harcourt et al.

JOURNAL OF VIROLOGY (2004)

Add to Collection

Article Biochemistry & Molecular Biology

WebLogo: A sequence logo generator

GE Crooks et al.

GENOME RESEARCH (2004)

Add to Collection

Article Multidisciplinary Sciences

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

WH Li et al.

NATURE (2003)

Add to Collection

Article Medicine, General & Internal

A major outbreak of severe acute respiratory syndrome in Hong Kong

N Lee et al.

NEW ENGLAND JOURNAL OF MEDICINE (2003)

Add to Collection

© Peeref 2019-2024. All rights reserved.